Recruiting OBSERVATIONAL NCT05867004

Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma (ATPIC)

Sponsor: Institut Claudius Regaud

Conditions Immune Defect Melanoma Tumor Skin

Updated 4 times since 2023 Last updated: May 27, 2025 Started: Jan 1, 2023 Primary completion: Jul 3, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Immune Defect and Melanoma and is currently actively recruiting participants. Institut Claudius Regaud leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Jun 2025 — Present [monthly]

Recruiting
Sep 2024 — Jun 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jun 2023 — Jul 2024 [monthly]

Recruiting

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Claudius Regaud
Institut National de la Santé Et de la Recherche Médicale, France

Data source: Institut Claudius Regaud

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toulouse, France